Property:Outcome specification
This is a property of type Text.
G
Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation +
Length of mucositis, daily assessed +
Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation +
Length of neutropenia (Neutrophil < 1000/mL) +
Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial +
NA +
Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial +
NA +
Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial +
Measured at baseline and after 3 years +
Gorgu et al. (2013): The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer +
NI +
Gorgu et al. (2013): The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer +
NI +
Gorgu et al. (2013): The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer +
NI +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
Self-reported "complete response" ("no vomiting", "no clinically significant nausea", defined as nausea <2 on a 10-point scale, and "no use of emergency medication") during the acute (0-24 h), delayed (24-120 h) and general phase (0-120 h) of chemotherapy with diary day -1 to 6 of each cycle) +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
Self-developed measurement instrument: structured checklist of cannabinoid-specific adverse events +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
Quality of life (nausea & vomiting scales) at baseline, day -1, end of treatment +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
Complete response, no vomiting or emergency medication 0-120h of chemotherapy +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
Disease response at the end of radiation (after 8 weeks) +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
Therapy result 5-6 months after completion of radiotherapy (at Follow-up 3) +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
'''Mucositis'''
Maximum extent: Evaluation for tissue responses for acute radiation side effects by grading mucositis at each visit
Grade of mucosits:
0 = nil
1 = mild
2 = moderate
3 = severe
Evaluation was continued at weekly intervals for 6 to 8 weeks covering the period of radiation therapy, and for another 5 to 6 month after the end of radiation therapy. The maximum score for the respective observation time were recorded. Grading was always done be the same investigator. +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
'''Onset of grade II side effects'''
Secondary criteria for efficacy was the time to reach a certain grade after commencement of radiation therapy; only patients with complete data set: Enzyme-arm: N=50, control-arm: N=43 +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
'''Skin reaction'''
Maximum extent: Evaluation for tissue responses for acute radiation side effects by grading skin reactions at each visit
Grade of skin reaction:
0 = nil
1 = erythema
2 = early desquamation/pigmentation
3 = moderate dry/ early moist desquamation
4 = blister formation/ skin peel
Evaluation was continued at weekly intervals for 6 to 8 weeks covering the period of radiation therapy, and for another 5 to 6 month after the end of radiation therapy. The maximum score for the respective observation time were recorded. Grading was always done be the same investigator. +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
'''Area under curve'''
Secondary criteria for efficacy were the areas under the curves in graphs for muscositis, skin reactions and dysphagia after commencement of radiation therapy. "Area under the curve" indicates the average score for muscositis, skin reactions and dysphagia; only patients with complete data set: Enzyme-arm: N=50, control-arm: N=43 +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
'''Dysphagia '''
Maximum extent: Evaluation for tissue responses for acute radiation side effects by grading dysphagia at each visit
Grade of dysphagia:
0 = nil
1 = for solids
2 = for semisolids
3 = for liquids
4 = requiring ryles tube/feeding gastrostomy
Evaluation was continued at weekly intervals for 6 to 8 weeks covering the period of radiation therapy, and for another 5 to 6 month after the end of radiation therapy. The maximum score for the respective observation time were recorded. Grading was always done be the same investigator. +
H
Hajimohammadebrahim-Ketabforoush et al. (2019): Effect of Vitamin D Supplementation on Postcraniotomy Pain After Brain Tumor Surgery: A Randomized Clinical Trial +
Postoperative pain (doses of analgesic medication consumption) +